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Despite successful restoration of epicardial coronary artery blood flow by primary 
percutaneous coronary intervention (PPCI), microvascular obstruction (MVO) occurs 
in about 50% of reperfused ST-segment elevation myocardial infarction (STEMI) 
patients.(1) MVO is caused by a complex interplay of factors including distal 
coronary embolization of plaque debris and thrombi; external compression of 
capillaries by edema; release of thrombogenic and vasoactive particles; neutrophil 
plugging; and extravasation of blood.(2) It is closely linked with the development of 
intramyocardial hemorrhage (IMH),(3) a complication of severe microvascular 
injury.(4)  
 Cardiovascular magnetic resonance (CMR) is considered to be the most 
reliable imaging modality for detecting MVO and IMH following STEMI.(5) Late 
MVO occurs in around 50-55%, and IMH in about 35-40% of reperfused STEMI 
patients.(1,6) Late MVO is more prognostic than early MVO,(6) and patients with late 
MVO persisting until 7 days post-PPCI have a worse prognosis.(7) Late MVO and 
IMH are both dynamic and follow distinct time courses within the first few days of 
STEMI.(8) Both late MVO and IMH are associated with larger MI sizes, adverse LV 
remodeling, and worse short- and medium-term clinical outcomes, and both predict 
outcomes independent of myocardial infarct (MI) size (1,6). Whether the presence of 
late MVO can predict long-term clinical outcomes beyond 2 years following STEMI 
was not previously known.  
In this issue of JACC: Cardiovascular Imaging, Symons et al (9) investigated 
the long-term incremental prognostic value of CMR over clinical predictors in STEMI 
patients treated by PPCI. They prospectively recruited 810 STEMI patients from 6 
European centers over a period of 12 years, and CMR was performed at a median of 4 
days following PPCI. After a median follow-up of 5.5 years, late MVO, both as a 
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continuous variable and as a binary measure, was demonstrated to be an independent 
predictor of the composite endpoint of all-cause death and decompensated heart 
failure. The authors found that the extent of late MVO of ≥2.6% of the left ventricle 
(LV) on the acute CMR scan, provided incremental prognostic value over clinical 
score and LV systolic function. This study extends the findings from previous studies 
that showed late MVO to be a strong independent prognostic marker following 
STEMI (1). The authors should be commended for completing a CMR study of this 
size in the acute STEMI setting, and for reporting the longest follow-up so far 
following PPCI. The particular strengths of this study include its multi-center design, 
centralized analysis of all CMR images, and manual quantification of MVO by 
experienced operators. There are, however, a few limitations to the study to be 
discussed, which serve to highlight the challenges of undertaking multi-center CMR 
studies of this magnitude in acute STEMI patients.  
There was likely a strong selection bias with the STEMI patient cohort 
investigated in this study, and the findings may not be representative of the real-world 
setting. STEMI patients selected for CMR evaluation are usually less sick, a reflected 
by the relatively low numbers of STEMI patients recruited over the 12 years 
(approximately 12 patients on average per center each year), the relatively small MI 
size observed in this study (15% versus 21% in a series of randomised controlled 
trials [RCTs])(10), and the lower incidence of late MVO in this patient cohort (44% 
versus over 50% in other published studies).(1)  
Although the CMR protocol was supposed to be standardized across the 6 
centers in this study, there were some differences in slice thickness and slice gap of 
the late gadolinium enhancement (LGE) sequences, and the choice of contrast agent 
and dose. A cut-off value of 2.6% of the LV for the extent of MVO was used in many 
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of their analyses and interpretations. However, it is well recognized that late MVO is 
dynamic, and its incidence and extent can be influenced by the timing of the acute 
CMR scan post-PPCI, the dosage and contrast agent used, and the timing of 
acquisition of the LGE images post-contrast injection.(7,8,11)  
Finally, it may have been more relevant to have determined the prognostic 
impact of late MVO on cardiac death and decompensated heart failure, instead of all-
cause death and decompensated heart failure, given the high incidence of non-cardiac 
deaths (41% of all death) due to the extended follow-up. 
The study findings also raise an interesting and thought-provoking question 
for the field. Is CMR ready for risk-stratification of STEMI patients in the clinical 
setting to guide management and improve outcomes? CMR in the acute STEMI 
patient has emerged as an important tool for assessing surrogate endpoints in 
RCTs,(10), for providing mechanistic insights into acute ischemia/reperfusion 
injury,(12,13) and for predicting clinical outcomes.(1,6) However, there is a lack of 
standardization in CMR protocols used in STEMI patients with respect to a number of 
factors including the timing of the CMR scan, the type and dose of contrast used, the 
timing of post-contrast LGE images, and the method used for MI size 
quantification.(10) Furthermore, performing a CMR study can be time-consuming, 
and requires numerous breath-holds, thereby precluding sicker patients from CMR 
studies. Crucially, once late MVO and/or IMH have been detected on the acute CMR 
scan, there is currently no established therapy for targeting these complications to 
improve clinical outcomes, although promising pre-clinical work is ongoing.(14) 
Therefore, as it stands, acute CMR in STEMI patients may not yet be ready for 
clinical application to guide management and improve clinical outcomes.  
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 There is, therefore, a need to standardize CMR protocols for acute scans 
performed in reperfused STEMI patients.(10) Furthermore, there is a requirement to 
shorten CMR scanning time using non breath-hold protocols, and a need to reduce 
costs, in order to make this imaging modality more accessible to a wider range of 
STEMI patients, and available in more centers. Only then can CMR, in combination 
with clinical prognostic factors such as late MVO demonstrated by Symons et al in 
their study,(9) be used as an important tool for risk-stratifying STEMI patients to 
guide management and improve clinical outcomes.  
 In summary, although CMR has greatly improved our understanding of the 
pathophysiological sequelae of reperfusion on the ischemic myocardium in STEMI 
patients treated by PPCI, and it has highlighted the key factors contributing to 
morbidity and mortality in the current era of PPCI, more work is needed before CMR 
can be used to risk-stratify reperfused STEMI patients in the clinical setting.  
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